Posts Tagged ‘Opportunities’

2 opportunities to help troops

2 opportunities to help troops
MASON — Area residents have two opportunities to lend their support to U.S. troops serving overseas.Operation: Thank You, a Warren County-based collection drive for troops overseas, will host its third annual fundraising event from 10 a.m. to 10 p.m. May 26 at Culvers restaurant on Tylersville Road in Mason.

Read more on The Western Star

Volunteer Opportunities

Volunteer Opportunities
American Red Cross Bay Area Chapter — Seeking volunteers in Contra Costa County for many positions, including clerical, disaster action team members and more. A great way to learn about disaster preparedness.

Read more on Oakley News

Targeting Cancer Stem Cells: Therapeutic Strategies, Drug Development Pipeline, Biomarkers and Diagnostic Opportunities 2010

Cancer Stem Cell (CSC) research has accelerated in the last two years and considerable efforts are now being made to identify drug molecules that selectively target and destroy them. Today, 50 developmental molecules are being evaluated in the hope of targeting this subset of cancer cells. More than 40 companies and commercial groups are progressing these activities and around 20 drug-targeting strategies are being evaluated. Efforts are being made to target CSCs using novel single agents as well as combinations, based on new and established classes. This 2010 report gives a comprehensive update on current therapeutic and diagnostic development in this field, on the drug development pipeline and the most promising research areas in CSC characterisation. New therapeutic and diagnostic opportunities in this field are also presented.

Background: Many cancers contain a subset of stem-like cells believed to play a critical role in the development and progression of the disease. These cells, named Cancer Stem Cells (CSCs), have been found in leukaemia, myeloma, breast, prostate, pancreatic, colon, brain, lung and other cancers. Findings suggest that CSCs are able to “seed” new tumour formation and drive metastasis. CSCs also show resistance to a number of chemotherapy drug classes and radiotherapy – which may explain why it is difficult to completely eradicate cancer cells from the body, and why recurrence remains an ever-present threat. If these findings are confirmed in the clinic, the targeting of CSCs alongside the bulk of other cancer cells will offer a new paradigm in cancer therapeutics. Currently, there are more than 50 CSC R&D programmes in progress, around 50% of which are at Phases I-III. Patient data from the first clinical trials on CSC-targeting drugs are now being reported. More than two thirds of CSC R&D programmes are being taken forward by SME’s, and >90% of the patents in this field have been filed by Universities. Substantial opportunity for collaboration exists in this field, and this has lead to agreements between SMEs and number of international pharmaceutical companies.

Drug Pipeline: Approximately 20 different strategies, which are described in this report, are being pursued in the hope of discovering ways of selectively targeting CSCs. Recently for example, at the CTRC-AACR San Antonio Breast Cancer Symposium in December 2009, data were presented on the targeting of chemotherapy-resistant breast CSCs with the Merck compound MK-0752, a gamma-secretase inhibitor that targets the Notch pathway. In a study involving 35 women with advanced breast cancer, biopsies revealed reduced numbers of breast CSCs. In this particular case, it was suggested that combination therapies involving agents that also target the Notch pathway (believed to be important in CSC renewal) may offer more powerful strategies for killing resistant CSC populations.

Cancer Diagnostics: CSCs are believed to be causally linked to the development and metastatic spread of cancer. If this is confirmed in the clinic, this will place CSCs at the heart of cancer diagnostics and biomarkers. Scientists have identified a number of surface proteins, such as CD44, CD133 and many others, that may have important utility in both of these areas. A number of intracellular markers found in CSCs may also have diagnostic utility. These developments are described in this report. For example, CD133 mRNA levels in peripheral blood, measured using RT-PCR, have been found to predict colon cancer recurrence. There is a need for new methodologies that isolate and characterise circulating tumour cells (CTCs) in the blood, and can be applied to CSCs. CTC technologies using the EpCam marker to isolate these cells are able to predict breast and colon cancer recurrence. The adaption of these techniques, based on specific CSC phenotypes, may provide sensitive new methods for identifying CSCs in the body. If this is achieved, it will have important implications in therapeutic decision-making and monitoring.

This 2010 report gives a comprehensive and up-to-date review of global R&D on CSCs, and strategies to target them. This includes around 40 companies or commercially based research organisations (including 27 SMEs and 8 international pharmaceutical companies) that are progressing drug discovery activities, including drug pipeline (pre-clinical to Phase III), discovery strategy, candidate molecules, drug targets, clinical trials and related areas.

For more information on the report, kindly visit :
http://www.visionshopsters.com/product/3358/Targeting-Cancer-Stem-Cells-Therapeutic-Strategies-Drug-Development-Pipeline-Biomarkers-and-Diagnostic-Opportunities-2010.html

or email us your query at :

Cancer Stem Cell (CSC) research has accelerated in the last two years and considerable efforts are now being made to identify drug molecules that selectively target and destroy them. Today, 50 developmental molecules are being evaluated in the hope of targeting this subset of cancer cells. More than 40 companies and commercial groups are progressing these activities and around 20 drug-targeting strategies are being evaluated. Efforts are being made to target CSCs using novel single agents as well as combinations, based on new and established classes. This 2010 report gives a comprehensive update on current therapeutic and diagnostic development in this field, on the drug development pipeline and the most promising research areas in CSC characterisation. New therapeutic and diagnostic opportunities in this field are also presented.

Background: Many cancers contain a subset of stem-like cells believed to play a critical role in the development and progression of the disease. These cells, named Cancer Stem Cells (CSCs), have been found in leukaemia, myeloma, breast, prostate, pancreatic, colon, brain, lung and other cancers. Findings suggest that CSCs are able to “seed” new tumour formation and drive metastasis. CSCs also show resistance to a number of chemotherapy drug classes and radiotherapy – which may explain why it is difficult to completely eradicate cancer cells from the body, and why recurrence remains an ever-present threat. If these findings are confirmed in the clinic, the targeting of CSCs alongside the bulk of other cancer cells will offer a new paradigm in cancer therapeutics. Currently, there are more than 50 CSC R&D programmes in progress, around 50% of which are at Phases I-III. Patient data from the first clinical trials on CSC-targeting drugs are now being reported. More than two thirds of CSC R&D programmes are being taken forward by SME’s, and >90% of the patents in this field have been filed by Universities. Substantial opportunity for collaboration exists in this field, and this has lead to agreements between SMEs and number of international pharmaceutical companies.

Drug Pipeline: Approximately 20 different strategies, which are described in this report, are being pursued in the hope of discovering ways of selectively targeting CSCs. Recently for example, at the CTRC-AACR San Antonio Breast Cancer Symposium in December 2009, data were presented on the targeting of chemotherapy-resistant breast CSCs with the Merck compound MK-0752, a gamma-secretase inhibitor that targets the Notch pathway. In a study involving 35 women with advanced breast cancer, biopsies revealed reduced numbers of breast CSCs. In this particular case, it was suggested that combination therapies involving agents that also target the Notch pathway (believed to be important in CSC renewal) may offer more powerful strategies for killing resistant CSC populations.

Cancer Diagnostics: CSCs are believed to be causally linked to the development and metastatic spread of cancer. If this is confirmed in the clinic, this will place CSCs at the heart of cancer diagnostics and biomarkers. Scientists have identified a number of surface proteins, such as CD44, CD133 and many others, that may have important utility in both of these areas. A number of intracellular markers found in CSCs may also have diagnostic utility. These developments are described in this report. For example, CD133 mRNA levels in peripheral blood, measured using RT-PCR, have been found to predict colon cancer recurrence. There is a need for new methodologies that isolate and characterise circulating tumour cells (CTCs) in the blood, and can be applied to CSCs. CTC technologies using the EpCam marker to isolate these cells are able to predict breast and colon cancer recurrence. The adaption of these techniques, based on specific CSC phenotypes, may provide sensitive new methods for identifying CSCs in the body. If this is achieved, it will have important implications in therapeutic decision-making and monitoring.

This 2010 report gives a comprehensive and up-to-date review of global R&D on CSCs, and strategies to target them. This includes around 40 companies or commercially based research organisations (including 27 SMEs and 8 international pharmaceutical companies) that are progressing drug discovery activities, including drug pipeline (pre-clinical to Phase III), discovery strategy, candidate molecules, drug targets, clinical trials and related areas.

For more information on the report, kindly visit :
http://www.visionshopsters.com/product/3358/Targeting-Cancer-Stem-Cells-Therapeutic-Strategies-Drug-Development-Pipeline-Biomarkers-and-Diagnostic-Opportunities-2010.html

or email us your query at : info@visionshopsters.com
———————————————-

The Cancer Market Outlook To 2014: Competitive Landscape, Market Size, Pipeline Analysis And Growth Opportunities

Most innovation in oncology over the past 10 years has been driven by scientific advances, particularly in genomics, transcriptomics and proteomics.

In the current environment, the successful oncology players of the future will be those that can anticipate protocol evolution and design the most relevant clinical trials. In recent years, biotech companies have fuelled innovation in oncology more than ever before. Partnering with biotech companies is a key (but expensive) source of innovation for many pharma companies as approximately 75% of phase II, III and pre-registration innovative drugs are of biotech origin.

At $47.7bn, cancer is one of the largest, fastest growing markets in the pharmaceutical industry. However, pricing risk remains the key investment concern in oncology. The key concern, however, is not price erosion driven by competitive forces, but price cuts imposed by payors irrespective of the fact that such unilateral price cuts by payors have never occurred in any of the major developed markets and would surely jeopardize the premise on which the entire biopharmaceutical industry has been built.

Key features of this report

• Epidemiological analysis and forecast prevalence of the major cancer indications over the period 2008-14 including lung, breast, colorectal, ovarian cancer markets.

• Forecasts and analysis of the major products in the cancer market over the period 2008-14 spread across the major indications and classes of treatments.

• Overview of key events in the global cancer market that have impacted treatment trends and sales potential across the major cancer indications.

• Strategic and growth analysis of leading pharmaceutical corporations based on sales focus by drug class, currently marketed products and R&D product portfolios.

Scope of this report

• Develop insight into patient potential with the report’s coverage of major indications in the cancer segment, the seven largest geographic pharmaceutical markets and 10 largest companies active in the cancer segment today

• Quickly understand how recent events are affecting the performance of major products, and how their marketers are confronting competitive changes in cancer marketplace

• Gain up-to-date competitive intelligence across the cancer indications and understand the major issues affecting key pharmaceutical/biotech players

• Understand which indications have the greatest potential to provide franchise growth, and how pharmaceutical companies are attempting to exploit these opportunities

Key Market Issues

• FDA approves Cervarix for cervical cancer
In October 2009, FDA approved GSK’s Cervarix for the prevention of pre-cancerous lesions caused by human papillomavirus (HPV) type 16 & 18 in women aged 10–25 years. Cervarix’s inclusion in children’s vaccine program is a major step towards securing reimbursement. Cervarix, expected to launch by the end of 2009, faces direct competition from Merck’s Gardasil and will help to reduce the incidence of cervical cancer in future.

• Merck’s Gardasil adds US indication of genital warts for boys and men
On 16th October 2009, Gardasil’s US label was extended to include its use in both men and boys aged 9–26 years of age. The pivotal trial results showed an efficacy of 90.4% while preventing external genital lesions of HPV types 6/11/16/18. In addition, Merck also planned to extend its vaccine patient assistance program providing free Gardasil to 19–26 year old uninsured males meeting eligibility criteria but unable to afford the vaccine.

Key findings from this report

• In 2008, antineoplastic mAbs delivered huge sales of $13.6bn with a market share of 28.6% of total sales. The key antineoplastic mAbs which contributed to the higher market share of this class in 2008 were MabThera (11.0%), Avastin (10.3%), Herceptin (9.7%) and Erbitux (3.4%). Forecast sales of the total antineoplastics market are estimated at $65.2bn in 2014.

• Roche is the global market leader in cancer, holding the highest market share of 29.2% ($14.0bn sales) in 2008 based on sales from (MabThera, Avastin, Herceptin, Tarceva and Xeloda). Roche’s strength in the cancer market has been bolstered by its acquisition of Genentech and purchase of majority stakes in Chugai, which has provided additional breadth to its portfolio.

• Eli Lilly’s acquisition of ImClone will increase the former’s flow of high-quality, innovative new therapies. The transaction will immediately enable Eli Lilly to offer physicians and their patients a complementary portfolio of leading oncolytic agents and targeted therapies including Gemzar, Alimta and Erbitux.

Key questions answered

• What will be the major growth indications in the cancer segment over the period 2008–14?

• Which companies were the winners and losers in the cancer segment in 2008?

• How have recent major launches from companies such as Roche, Sanofi-Aventis, AstraZeneca, Novartis and Eli Lilly performed?

• Which companies will become the key players in the cancer segment over the period 2008–14?

• Which products will be impacted by generic competitors over the period 2008–14
 
 
  Table of Contents : 
Table of Contents
The Cancer Market Outlook to 2014
Executive Summary 12
Epidemiology of Cancer 12
Global Market Analysis 13
Pipeline Analysis 14
Competitive Landscape 15
Chapter 1 Scope and methodology 18
Scope 18
Methodology 19
Chapter 2 Overview and epidemiology of cancer indications 22
Summary 22
Introduction 23
Overview 23
Cancer risk factors 23
Lung cancer 24
Overview 24
Diagnosis, treatment and management 25
Epidemiology 27
NSCLC 27
SCLC 28
Forecast epidemiology 29
NSCLC 29
SCLC 30
Colorectal cancer 31
Overview 31
Diagnosis, treatment and management 31
Epidemiology 32
Forecast epidemiology 33
Breast cancer 34
Overview 34
Diagnosis, treatment and management 35
Epidemiology 36
Forecast epidemiology 37
Ovarian cancer 38
Overview 38
Diagnosis, treatment and management 39
Epidemiology 40
Forecast epidemiology 41
Uterine and cervical cancer 42
Overview 42
Diagnosis, treatment and management 43
Epidemiology 44
Forecast epidemiology 44
Leukemia 45
Overview 45
Diagnosis, treatment and management 47
Epidemiology 48
Forecast epidemiology 48
Prostate cancer 49
Overview 49
Diagnosis, treatment and management 50
Epidemiology 51
Forecast epidemiology 51
Pancreatic cancer 53
Overview 53
Diagnosis, treatment and management 53
Epidemiology 54
Forecast epidemiology 54
Lymphomas 56
Overview 56
Diagnosis, treatment and management 56
Epidemiology 57
Forecast epidemiology 58
Head and neck cancer 60
Overview 60
Diagnosis, treatment and management 61
Epidemiology 62
Forecast epidemiology 62
Chapter 3 Global market analysis 66
Summary 66
Introduction 67
Market analysis by country 67
Market analysis by drug class 69
Leading brand dynamics 70
MabThera (rituximab) –Roche/Genentech 71
Avastin (bevacizumab) – Roche/Genentech 73
Herceptin (trastuzumab) – Roche/Genentech/Chugai 74
Glivec/Gleevec (imatinib) – Novartis 75
Taxotere (docetaxel) – Sanofi-Aventis 76
Leading brands by type of cancer 77
Key recent events in the cancer market 80
FDA approves Cervarix for cervical cancer 80
Merck’s Gardasil adds US indication of genital warts for boys and men 80
Roche’s Avastin is filed for first-line breast cancer in Japan 80
Eisai to file first in-house breast cancer drug in major markets 81
Novartis’s Tasigna bolsters its CML franchise 81
Antineoplastics 82
Competitive dynamics of antineoplastics 82
Leading brands of antineoplastics 84
Antineoplastic mAb market analysis 86
Market dynamics 86
Key brands analysis 86
Antineoplastic protein kinase inhibitors 88
Market dynamics 88
Key brands analysis 89
Vinca alkaloid market analysis 89
Market dynamics 89
Key brands analysis 90
Anti-metabolites 90
Market dynamics 90
Key brands analysis 90
Platinum compounds 92
Market dynamics 92
Key brands analysis 92
Antineoplastic sales forecast 93
Cytostatic hormonal therapies 94
Competitive dynamics of cytostatic hormonal therapies 94
Leading brands of cytostatic hormonal therapies 95
Cytostatic gonad hormone analog market analysis 97
Market dynamics 97
Key brands analysis 97
Aromatase inhibitors 98
Market dynamics 98
Key brands analysis 99
Anti-androgens 101
Market dynamics 101
Key brand analysis 102
Cytostatic hormonal therapy sales forecast 103
Global cancer market sales forecast 104
Chapter 4 Pipeline analysis 106
Summary 106
Introduction 107
Key trends in R&D 107
Targeted therapies are changing the treatment regimen of cancer 107
Biomarkers are personalizing oncology treatment 108
Cancer vaccines enhance the body’s immune response 109
Pricing is becoming a major issue for cancer patients 109
Combination treatments are becoming the treatment of choice 110
Leading drugs in development 111
Phase III and pending approval compounds 112
Enzastaurin – Eli Lilly 112
BiovaxID – Biovest International and Accentia Biopharmaceuticals 115
Recentin (cediranib) – AstraZeneca 117
Zactima (vandetanib) – AstraZeneca 120
Axitinib (AG-13736) – Pfizer 124
Provenge (sipuleucel-T) – Dendreon 126
Recently approved/marketed drugs 127
Arzerra (ofatumumab) – GSK/Genmab 127
Afinitor (everolimus) – Novartis 130
Iressa (gefitinib) – AstraZeneca 132
Tykerb/Tyverb (lapatinib) – GSK 133
Votrient (pazopanib) – GSK 137
Pipeline forecast of key compounds 139
Factors affecting forecasts 139
Chapter 5 Competitive landscape 142
Summary 142
Introduction 143
Sales performance of leading players 143
Roche 146
Sales focus by drug class 146
Regional sales distribution 147
Marketed product portfolio 148
Pipeline analysis 150
Strategic and growth analysis 151
Drivers of growth 151
Resistors of growth 152
Sanofi–Aventis 153
Sales focus by drug class 153
Regional sales distribution 154
Marketed product portfolio 155
Pipeline analysis 156
Strategic and growth analysis 157
Drivers of growth 157
Resistors of growth 158
AstraZeneca 159
Sales focus by drug class 159
Regional sales distribution 160
Marketed product portfolio 161
Pipeline analysis 162
Strategic and growth analysis 163
Drivers of growth 163
Resistors of growth 163
Novartis 164
Sales focus by drug class 164
Regional sales distribution 165
Marketed product portfolio 166
Pipeline analysis 167
Strategic and growth analysis 168
Drivers of growth 168
Resistors of growth 168
Eli Lilly 169
Sales focus by drug class 169
Regional sales distribution 169
Marketed product portfolio 170
Pipeline analysis 171
Strategic and growth analysis 171
Drivers of growth 171
Resistors of growth 172
Pfizer 173
Sales focus by drug class 173
Regional sales distribution 174
Marketed product portfolio 175
Pipeline analysis 176
Strategic and growth analysis 177
Drivers of growth 177
Resistors of growth 177
Takeda 177
Sales focus by drug class 178
Regional sales distribution 179
Marketed product portfolio 179
Pipeline analysis 180
Strategic and growth analysis 181
Drivers of growth 181
Resistors of growth 181
Bristol-Myers Squibb 182
Sales focus by drug class 182
Regional sales distribution 183
Marketed product portfolio 184
Pipeline analysis 185
Strategic and growth analysis 186
Drivers of growth 186
Resistors of growth 186
Chapter 6 Appendix 188
IMS Data 188
Antineoplastic and immunomodulating agents 188
L1: Antineoplastics 188
L2: Cytostatic hormone therapy 188
Forecast factors 188
Glossary 189
Abbreviations used in this report 189
Index 191

List of Figures
Figure 2.1: Types of breast cancers 35
Figure 2.2: Types of leukemia 46
Figure 2.3: Chemotherapy options for Hodgkin’s disease 57
Figure 2.4: Head and neck cancers and their risk factors 60
Figure 3.5: Worldwide cancer market share by region, 2008 69
Figure 4.6: Current pharmacological treatment options for cancer 111
Figure 4.7: Key drugs in late-stage development or that have been recently launched 112
Figure 5.8: Contribution of the top 10 players to growth of the global cancer market, 2007–08 145
Figure 5.9: Roche’s cancer sales by drug class, 2008 146
Figure 5.10: Sanofi–Aventis’s cancer sales by drug class, 2008 153
Figure 5.11: AstraZeneca’s cancer sales by drug class, 2008 159
Figure 5.12: Novartis’s cancer sales by drug class, 2008 164
Figure 5.13: Pfizer’s cancer sales by drug class, 2008 173
Figure 5.14: Takeda’s cancer sales by drug class, 2008 178
Figure 5.15: BMS’ cancer sales by drug class, 2008 182

List of Tables
Table 2.1: Estimated prevalence of NSCLC across seven major markets, 2008 27
Table 2.2: Estimated prevalence of SCLC across seven major markets, 2008 28
Table 2.3: Forecast epidemiology of NSCLC across seven major markets, 2008–14 29
Table 2.4: Forecast epidemiology of SCLC across seven major markets, 2008–14 30
Table 2.5: Estimated prevalence of colorectal cancer across seven major markets, 2008 33
Table 2.6: Forecast epidemiology of colorectal cancer across seven major markets, 2008–14 34
Table 2.7: Estimated prevalence of breast cancer across seven major markets, 2008 36
Table 2.8: Forecast epidemiology of breast cancer across seven major markets, 2008–14 38
Table 2.9: Estimated prevalence of ovarian cancer across seven major markets, 2008 40
Table 2.10: Forecast epidemiology of ovarian cancer across seven major markets, 2008–14 42
Table 2.11: Estimated prevalence of uterine and cervical cancer across seven major markets, 2008 44
Table 2.12: Forecast epidemiology of uterine and cervical cancer across seven major markets, 2008–14 45
Table 2.13: Estimated prevalence of leukemia across seven major markets, 2008 48
Table 2.14: Forecast epidemiology of leukemia across seven major markets, 2008–14 49
Table 2.15: Estimated prevalence of prostate cancer across seven major markets, 2008 51
Table 2.16: Forecast epidemiology of prostate cancer across seven major markets, 2008–14 52
Table 2.17: Estimated prevalence of pancreatic cancer across seven major markets, 2008 54
Table 2.18: Forecast epidemiology of pancreatic cancer across seven major markets, 2008–14 55
Table 2.19: Estimated prevalence of lymphomas across seven major markets, 2008 58
Table 2.20: Forecast epidemiology of lymphomas across seven major markets, 2008–14 59
Table 2.21: Estimated prevalence of head and neck cancer across seven major markets, 2008 62
Table 2.22: Forecast epidemiology of head and neck cancer across seven major markets, 2008–14 63
Table 3.23: Global cancer market by geography, 2008 68
Table 3.24: Breakdown of the global cancer market by drug class, 2008 69
Table 3.25: Leading brands in the global cancer market, 2008 71
Table 3.26: Leading brands in breast cancer, 2008 78
Table 3.27: Leading brands in colon cancer, 2008 78
Table 3.28: Leading brands in prostate cancer, 2008 79
Table 3.29: Leading brands in lung cancer, 2008 79
Table 3.30: Breakdown of the global antineoplastic market by drug class, 2008 83
Table 3.31: Leading brands in global antineoplastics market, 2008 85
Table 3.32: Chronology of new indication approvals for Eloxatine 93
Table 3.33: Antineoplastic sales forecast, 2008–14 93
Table 3.34: Breakdown of the global cytostatic hormonal therapies by drug class, 2008 95
Table 3.35: Leading brands in global cytostatic hormonal therapies market, 2008 96
Table 3.36: Cytostatic hormonal therapy sales forecast, 2008–14 103
Table 3.37: Global cancer market sales forecast, 2008–14 104
Table 4.38: An overview of enzastaurin 112
Table 4.39: An overview of BiovaxID 115
Table 4.40: An overview of Recentin 117
Table 4.41: The Horizon Study Program 118
Table 4.42: An overview of Zactima 120
Table 4.43: Overview of Zactima’s Phase III development plan 122
Table 4.44: An overview of axitinib 124
Table 4.45: An overview of Provenge 126
Table 4.46: An overview of Arzerra 127
Table 4.47: An overview of Afinitor 130
Table 4.48: An overview of Iressa 132
Table 4.49: An overview of Tykerb/Tyverb 133
Table 4.50: An overview of Votrient 137
Table 4.51: Key pipeline and recently approved products sales forecast, 2008–14 139
Table 5.52: Leading players in the global cancer market, 2008–14 143
Table 5.53: Regional sales distribution of Roche, 2008 147
Table 5.54: Roche’s cancer product portfolio, 2008 148
Table 5.55: Roche’s cancer R&D product pipeline, October 2009 150
Table 5.56: Regional sales distribution of Sanofi-Aventis, 2008 154
Table 5.57: Sanofi–Aventis’s cancer product portfolio, 2008 155
Table 5.58: Sanofi-Aventis’s cancer R&D product pipeline, October 2009 156
Table 5.59: Regional sales distribution of AstraZeneca, 2008 160
Table 5.60: AstraZeneca’s cancer product portfolio, 2008 161
Table 5.61: AstraZeneca’s cancer R&D product pipeline, October 2009 162
Table 5.62: Regional sales distribution of Novartis, 2008 165
Table 5.63: Novartis’ cancer product portfolio, 2008 166
Table 5.64: Novartis’s cancer R&D product pipeline, October 2009 167
Table 5.65: Regional sales distribution of Eli Lilly, 2008 169
Table 5.66: Eli Lilly’s cancer product portfolio, 2008 170
Table 5.67: Eli Lilly’s cancer R&D product pipeline, October 2009 171
Table 5.68: Regional sales distribution of Pfizer, 2008 174
Table 5.69: Pfizer’s cancer product portfolio, 2008 175
Table 5.70: Pfizer’s cancer R&D product pipeline, October 2009 176
Table 5.71: Regional sales distribution of Takeda, 2008 179
Table 5.72: Takeda’s cancer product portfolio, 2008 179
Table 5.73: Takeda’s cancer R&D product pipeline, October 2009 180
Table 5.74: Regional sales distribution of BMS, 2008 183
Table 5.75: BMS’ cancer product portfolio, 2008 184
Table 5.76: BMS’ cancer R&D product pipeline, October 2009 185
 
 

For More information please contact :

http://www.aarkstore.com/reports/The-Cancer-Market-Outlook-To-2014-Competitive-landscape-market-size-pipeline-analysis-and-growth-opportunities-36780.html

The Cancer Market Outlook To 2014: Competitive Landscape, Market Size, Pipeline Analysis And Growth Opportunities Report

In the current decade, oncology has been one of the most important growth segments among the pharmaceutical markets with a major focus on targeted agents (drug treatments developed to preferentially target those signaling pathways that are disregulated in tumors). Most innovation in oncology over the past 10 years has been driven by scientific advances, particularly in genomics, transcriptomics and proteomics.

In the current environment, the successful oncology players of the future will be those that can anticipate protocol evolution and design the most relevant clinical trials. In recent years, biotech companies have fuelled innovation in oncology more than ever before. Partnering with biotech companies is a key (but expensive) source of innovation for many pharma companies as approximately 75% of phase II, III and pre-registration innovative drugs are of biotech origin.

At $47.7bn, cancer is one of the largest, fastest growing markets in the pharmaceutical industry. However, pricing risk remains the key investment concern in oncology. The key concern, however, is not price erosion driven by competitive forces, but price cuts imposed by payors irrespective of the fact that such unilateral price cuts by payors have never occurred in any of the major developed markets and would surely jeopardize the premise on which the entire biopharmaceutical industry has been built.

Key features of this report

Epidemiological analysis and forecast prevalence of the major cancer indications over the period 2008-14 including lung, breast, colorectal, ovarian cancer markets.
Forecasts and analysis of the major products in the cancer market over the period 2008-14 spread across the major indications and classes of treatments.
Overview of key events in the global cancer market that have impacted treatment trends and sales potential across the major cancer indications.
Strategic and growth analysis of leading pharmaceutical corporations based on sales focus by drug class, currently marketed products and R&D product portfolios.

Scope of this report

Develop insight into patient potential with the report’s coverage of major indications in the cancer segment, the seven largest geographic pharmaceutical markets and 10 largest companies active in the cancer segment today
Quickly understand how recent events are affecting the performance of major products, and how their marketers are confronting competitive changes in cancer marketplace
Gain up-to-date competitive intelligence across the cancer indications and understand the major issues affecting key pharmaceutical/biotech players
Understand which indications have the greatest potential to provide franchise growth, and how pharmaceutical companies are attempting to exploit these opportunities

Key Market Issues

FDA approves Cervarix for cervical cancer

In October 2009, FDA approved GSK’s Cervarix for the prevention of pre-cancerous lesions caused by human papillomavirus (HPV) type 16 & 18 in women aged 10-25 years. Cervarix’s inclusion in children’s vaccine program is a major step towards securing reimbursement. Cervarix, expected to launch by the end of 2009, faces direct competition from Merck’s Gardasil and will help to reduce the incidence of cervical cancer in future.

Merck’s Gardasil adds US indication of genital warts for boys and men

On 16th October 2009, Gardasil’s US label was extended to include its use in both men and boys aged 9-26 years of age. The pivotal trial results showed an efficacy of 90.4% while preventing external genital lesions of HPV types 6/11/16/18. In addition, Merck also planned to extend its vaccine patient assistance program providing free Gardasil to 19-26 year old uninsured males meeting eligibility criteria but unable to afford the vaccine.

Key findings from this report

In 2008, antineoplastic mAbs delivered huge sales of $13.6bn with a market share of 28.6% of total sales. The key antineoplastic mAbs which contributed to the higher market share of this class in 2008 were MabThera (11.0%), Avastin (10.3%), Herceptin (9.7%) and Erbitux (3.4%). Forecast sales of the total antineoplastics market are estimated at $65.2bn in 2014.
Roche is the global market leader in cancer, holding the highest market share of 29.2% ($14.0bn sales) in 2008 based on sales from (MabThera, Avastin, Herceptin, Tarceva and Xeloda). Roche’s strength in the cancer market has been bolstered by its acquisition of Genentech and purchase of majority stakes in Chugai, which has provided additional breadth to its portfolio.
Eli Lilly’s acquisition of ImClone will increase the former’s flow of high-quality, innovative new therapies. The transaction will immediately enable Eli Lilly to offer physicians and their patients a complementary portfolio of leading oncolytic agents and targeted therapies including Gemzar, Alimta and Erbitux.

Key questions answered

What will be the major growth indications in the cancer segment over the period 2008-14?
Which companies were the winners and losers in the cancer segment in 2008?
How have recent major launches from companies such as Roche, Sanofi-Aventis, AstraZeneca, Novartis and Eli Lilly performed?
Which companies will become the key players in the cancer segment over the period 2008-14?
Which products will be impacted by generic competitors over the period 2008-14?

Report Description:

In the current decade, oncology has been one of the most important growth segments among the pharmaceutical markets with a major focus on targeted agents (drug treatments developed to preferentially target those signaling pathways that are disregulated in tumors). Most innovation in oncology over the past 10 years has been driven by scientific advances, particularly in genomics, transcriptomics and proteomics.

In the current environment, the successful oncology players of the future will be those that can anticipate protocol evolution and design the most relevant clinical trials. In recent years, biotech companies have fuelled innovation in oncology more than ever before. Partnering with biotech companies is a key (but expensive) source of innovation for many pharma companies as approximately 75% of phase II, III and pre-registration innovative drugs are of biotech origin.

At $47.7bn, cancer is one of the largest, fastest growing markets in the pharmaceutical industry. However, pricing risk remains the key investment concern in oncology. The key concern, however, is not price erosion driven by competitive forces, but price cuts imposed by payors irrespective of the fact that such unilateral price cuts by payors have never occurred in any of the major developed markets and would surely jeopardize the premise on which the entire biopharmaceutical industry has been built.

Key features of this report

Epidemiological analysis and forecast prevalence of the major cancer indications over the period 2008-14 including lung, breast, colorectal, ovarian cancer markets.
Forecasts and analysis of the major products in the cancer market over the period 2008-14 spread across the major indications and classes of treatments.
Overview of key events in the global cancer market that have impacted treatment trends and sales potential across the major cancer indications.
Strategic and growth analysis of leading pharmaceutical corporations based on sales focus by drug class, currently marketed products and R&D product portfolios.

Scope of this report

Develop insight into patient potential with the report’s coverage of major indications in the cancer segment, the seven largest geographic pharmaceutical markets and 10 largest companies active in the cancer segment today
Quickly understand how recent events are affecting the performance of major products, and how their marketers are confronting competitive changes in cancer marketplace
Gain up-to-date competitive intelligence across the cancer indications and understand the major issues affecting key pharmaceutical/biotech players
Understand which indications have the greatest potential to provide franchise growth, and how pharmaceutical companies are attempting to exploit these opportunities

Key Market Issues

FDA approves Cervarix for cervical cancer

In October 2009, FDA approved GSK’s Cervarix for the prevention of pre-cancerous lesions caused by human papillomavirus (HPV) type 16 & 18 in women aged 10-25 years. Cervarix’s inclusion in children’s vaccine program is a major step towards securing reimbursement. Cervarix, expected to launch by the end of 2009, faces direct competition from Merck’s Gardasil and will help to reduce the incidence of cervical cancer in future.

Merck’s Gardasil adds US indication of genital warts for boys and men

On 16th October 2009, Gardasil’s US label was extended to include its use in both men and boys aged 9-26 years of age. The pivotal trial results showed an efficacy of 90.4% while preventing external genital lesions of HPV types 6/11/16/18. In addition, Merck also planned to extend its vaccine patient assistance program providing free Gardasil to 19-26 year old uninsured males meeting eligibility criteria but unable to afford the vaccine.

Key findings from this report

In 2008, antineoplastic mAbs delivered huge sales of $13.6bn with a market share of 28.6% of total sales. The key antineoplastic mAbs which contributed to the higher market share of this class in 2008 were MabThera (11.0%), Avastin (10.3%), Herceptin (9.7%) and Erbitux (3.4%). Forecast sales of the total antineoplastics market are estimated at $65.2bn in 2014.
Roche is the global market leader in cancer, holding the highest market share of 29.2% ($14.0bn sales) in 2008 based on sales from (MabThera, Avastin, Herceptin, Tarceva and Xeloda). Roche’s strength in the cancer market has been bolstered by its acquisition of Genentech and purchase of majority stakes in Chugai, which has provided additional breadth to its portfolio.
Eli Lilly’s acquisition of ImClone will increase the former’s flow of high-quality, innovative new therapies. The transaction will immediately enable Eli Lilly to offer physicians and their patients a complementary portfolio of leading oncolytic agents and targeted therapies including Gemzar, Alimta and Erbitux.

Key questions answered

What will be the major growth indications in the cancer segment over the period 2008-14?
Which companies were the winners and losers in the cancer segment in 2008?
How have recent major launches from companies such as Roche, Sanofi-Aventis, AstraZeneca, Novartis and Eli Lilly performed?
Which companies will become the key players in the cancer segment over the period 2008-14?
Which products will be impacted by generic competitors over the period 2008-14?

Table of Contents:  The Cancer Market Outlook to 2014

Executive Summary 12
Epidemiology of Cancer 12
Global Market Analysis 13
Pipeline Analysis 14
Competitive Landscape 15

Chapter 1 Scope and methodology 18
Scope 18
Methodology 19

Chapter 2 Overview and epidemiology of cancer indications 22
Summary 22
Introduction 23
Overview 23
Cancer risk factors 23
Lung cancer 24
Overview 24
Diagnosis, treatment and management 25
Epidemiology 27
NSCLC 27
SCLC 28
Forecast epidemiology 29
NSCLC 29
SCLC 30
Colorectal cancer 31
Overview 31
Diagnosis, treatment and management 31
Epidemiology 32
Forecast epidemiology 33
Breast cancer 34
Overview 34
Diagnosis, treatment and management 35
Epidemiology 36
Forecast epidemiology 37
Ovarian cancer 38
Overview 38
Diagnosis, treatment and management 39
Epidemiology 40
Forecast epidemiology 41
Uterine and cervical cancer 42
Overview 42
Diagnosis, treatment and management 43
Epidemiology 44
Forecast epidemiology 44
Leukemia 45
Overview 45
Diagnosis, treatment and management 47
Epidemiology 48
Forecast epidemiology 48
Prostate cancer 49
Overview 49
Diagnosis, treatment and management 50
Epidemiology 51
Forecast epidemiology 51
Pancreatic cancer 53
Overview 53
Diagnosis, treatment and management 53
Epidemiology 54
Forecast epidemiology 54
Lymphomas 56
Overview 56
Diagnosis, treatment and management 56
Epidemiology 57
Forecast epidemiology 58
Head and neck cancer 60
Overview 60
Diagnosis, treatment and management 61
Epidemiology 62
Forecast epidemiology 62

Chapter 3 Global market analysis 66
Summary 66
Introduction 67
Market analysis by country 67
Market analysis by drug class 69
Leading brand dynamics 70
MabThera (rituximab) –Roche/Genentech 71
Avastin (bevacizumab) – Roche/Genentech 73
Herceptin (trastuzumab) – Roche/Genentech/Chugai 74
Glivec/Gleevec (imatinib) – Novartis 75
Taxotere (docetaxel) – Sanofi-Aventis 76
Leading brands by type of cancer 77
Key recent events in the cancer market 80
FDA approves Cervarix for cervical cancer 80
Merck’s Gardasil adds US indication of genital warts for boys and men 80
Roche’s Avastin is filed for first-line breast cancer in Japan 80
Eisai to file first in-house breast cancer drug in major markets 81
Novartis’s Tasigna bolsters its CML franchise 81
Antineoplastics 82
Competitive dynamics of antineoplastics 82
Leading brands of antineoplastics 84
Antineoplastic mAb market analysis 86
Market dynamics 86
Key brands analysis 86
Antineoplastic protein kinase inhibitors 88
Market dynamics 88
Key brands analysis 89
Vinca alkaloid market analysis 89
Market dynamics 89
Key brands analysis 90
Anti-metabolites 90
Market dynamics 90
Key brands analysis 90
Platinum compounds 92
Market dynamics 92
Key brands analysis 92
Antineoplastic sales forecast 93
Cytostatic hormonal therapies 94
Competitive dynamics of cytostatic hormonal therapies 94
Leading brands of cytostatic hormonal therapies 95
Cytostatic gonad hormone analog market analysis 97
Market dynamics 97
Key brands analysis 97
Aromatase inhibitors 98
Market dynamics 98
Key brands analysis 99
Anti-androgens 101
Market dynamics 101
Key brand analysis 102
Cytostatic hormonal therapy sales forecast 103
Global cancer market sales forecast 104

Chapter 4 Pipeline analysis 106
Summary 106
Introduction 107
Key trends in R&D 107
Targeted therapies are changing the treatment regimen of cancer 107
Biomarkers are personalizing oncology treatment 108
Cancer vaccines enhance the body’s immune response 109
Pricing is becoming a major issue for cancer patients 109
Combination treatments are becoming the treatment of choice 110
Leading drugs in development 111
Phase III and pending approval compounds 112
Enzastaurin – Eli Lilly 112
BiovaxID – Biovest International and Accentia Biopharmaceuticals 115
Recentin (cediranib) – AstraZeneca 117
Zactima (vandetanib) – AstraZeneca 120
Axitinib (AG-13736) – Pfizer 124
Provenge (sipuleucel-T) – Dendreon 126
Recently approved/marketed drugs 127
Arzerra (ofatumumab) – GSK/Genmab 127
Afinitor (everolimus) – Novartis 130
Iressa (gefitinib) – AstraZeneca 132
Tykerb/Tyverb (lapatinib) – GSK 133
Votrient (pazopanib) – GSK 137
Pipeline forecast of key compounds 139
Factors affecting forecasts 139

Chapter 5 Competitive landscape 142
Summary 142
Introduction 143
Sales performance of leading players 143
Roche 146
Sales focus by drug class 146
Regional sales distribution 147
Marketed product portfolio 148
Pipeline analysis 150
Strategic and growth analysis 151
Drivers of growth 151
Resistors of growth 152
Sanofi–Aventis 153
Sales focus by drug class 153
Regional sales distribution 154
Marketed product portfolio 155
Pipeline analysis 156
Strategic and growth analysis 157
Drivers of growth 157
Resistors of growth 158
AstraZeneca 159
Sales focus by drug class 159
Regional sales distribution 160
Marketed product portfolio 161
Pipeline analysis 162
Strategic and growth analysis 163
Drivers of growth 163
Resistors of growth 163
Novartis 164
Sales focus by drug class 164
Regional sales distribution 165
Marketed product portfolio 166
Pipeline analysis 167
Strategic and growth analysis 168
Drivers of growth 168
Resistors of growth 168
Eli Lilly 169
Sales focus by drug class 169
Regional sales distribution 169
Marketed product portfolio 170
Pipeline analysis 171
Strategic and growth analysis 171
Drivers of growth 171
Resistors of growth 172
Pfizer 173
Sales focus by drug class 173
Regional sales distribution 174
Marketed product portfolio 175
Pipeline analysis 176
Strategic and growth analysis 177
Drivers of growth 177
Resistors of growth 177
Takeda 177
Sales focus by drug class 178
Regional sales distribution 179
Marketed product portfolio 179
Pipeline analysis 180
Strategic and growth analysis 181
Drivers of growth 181
Resistors of growth 181
Bristol-Myers Squibb 182
Sales focus by drug class 182
Regional sales distribution 183
Marketed product portfolio 184
Pipeline analysis 185
Strategic and growth analysis 186
Drivers of growth 186
Resistors of growth 186

Chapter 6 Appendix 188
IMS Data 188
Antineoplastic and immunomodulating agents 188
L1: Antineoplastics 188
L2: Cytostatic hormone therapy 188
Forecast factors 188
Glossary 189
Abbreviations used in this report 189
Index 191